secwatch / observer
8-K filed October 10, 2023, 7:59 PM ET ticker MLAB CIK 0000724004
debt confidence high sentiment neutral materiality 0.35

MESA LABORATORIES INC /CO/ (MLAB): debt financing — Mesa Labs increases revolving credit facility to $125M from $75M

MESA LABORATORIES INC /CO/

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

MESA LABORATORIES INC /CO/ amended revolving credit of $125.0 million with JPMorgan Chase Bank, N.A..

Instrument
revolving credit
Principal
$125.0 million
Counterparty
JPMorgan Chase Bank, N.A.
Event
amendment
Exact text from the filing
Chase Bank, N.A., as administrative agent. The terms of the original credit agreement, as amended, have not changed, except: 1) The Revolving Commitment has been increased to $125.0 million, from $75.0 million; and 2) Certain administrative amendments have been made to accommodate changes in the business. As of the date of this Form 8-K, no amounts have been drawn
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MESA LABORATORIES INC /CO/ entered into Senior Secured Credit Agreement with JPMorgan Chase Bank, N.A. valued at Revolving Commitment increased to $125.0 million (effective 2023-10-05).

Action
entry
Agreement
credit facility
Counterparty
JPMorgan Chase Bank, N.A.
Value
Revolving Commitment increased to $125.0 million
Effective
2023-10-05
Exact text from the filing
On October 5, 2023, Mesa Laboratories, Inc. (the “Company”) amended its four-year senior secured credit agreement (the “Credit Agreement”) with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.
View on SEC.gov

Browse all debt financings →

MESA LABORATORIES INC /CO/ filing history →

Source: SEC EDGAR
accession 0001437749-23-027935
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.